| abstract |
Compounds are described which potentiate glutamate receptor and applications thereof in medicine. Compounds of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug are disclosed wherein R 1 is C 1-6 alkyl, haloC 1-6 alkyl, C 2-6 alkenyl, amino, monoC 1-4 alkylamino or diC 1-4 alkylamino; R 2 and R 3 which may be the same or different are hydrogen, halogen, C 1-6 alkyl, halogen C 1-6 alkyl, C 1-4 alkoxy, halogen C 1-4 alkoxy, cyano, amino, monoC 1-4 alkylamino or diC 1-4 alkylamino; each R 4, which may be the same or different, is C 1-6 alkyl, halogen, halogen C 1-6 alkyl, C 1-4 alkoxy, halogen C 1-4 alkoxy, cyano, nitro, amino, monoC 1-4 alkylamino or diC 1-4 alkylamino; p is 0, 1 or 2; n is 1 or 2; R 5 and R 6, which may be the same or different, are hydrogen, halogen, C 1-6 alkyl, halogen C 1-6 alkyl, C 1-4 alkoxy, halogen C 1-4 alkoxy, cyano, amino, monoC 1-4 alkylamino or diC 1-4 alkylamino; and Het is thienyl, pyridyl, pyrimidinyl, pyridazinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, pyrrolyl, quinolyl, thiazolyl or furyl, each of which may be substituted by one or more groups independently selected from the list consisting of C 1-6 alkyl, C 1-6 alkoxy. , acetyl, halogen, halogen C1-6 alkyl, cyano, nitro, amino, monoC1-4 alkylamino and diC1-4alkylamino. Methods are further described for the preparation of the compounds and their applications in medicine, for example for the treatment of schizophrenia. |